Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Oral phosphate binders in patients with kidney failure.

Tonelli M, Pannu N, Manns B.

N Engl J Med. 2010 Apr 8;362(14):1312-24. doi: 10.1056/NEJMra0912522. Review. No abstract available.

PMID:
20375408
2.

A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.

Sprague SM.

Curr Med Res Opin. 2007 Dec;23(12):3167-75. Review. Erratum in: Curr Med Res Opin. 2008 Mar;24(3):708.

PMID:
17991307
3.

Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.

Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF.

Am J Kidney Dis. 2009 Oct;54(4):619-37. doi: 10.1053/j.ajkd.2009.06.004. Epub 2009 Aug 18. Review.

PMID:
19692157
4.

Does concomitant administration of sevelamer hydrochloride and lanthanum carbonate modify the control of phosphatemia?

Senatore M, Coppolino G, Papalia T, Greco R, Lofaro D, Bonofiglio R.

Eur Rev Med Pharmacol Sci. 2011 Nov;15(11):1352-4. No abstract available.

PMID:
22195373
5.

A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.

Prajapati VA, Galani VJ, Shah PR.

Saudi J Kidney Dis Transpl. 2014 May;25(3):530-8.

6.

Phosphate binders in CKD: chalking out the differences.

Rees L, Shroff RC.

Pediatr Nephrol. 2010 Mar;25(3):385-94. doi: 10.1007/s00467-009-1329-0. Epub 2009 Nov 7. Review.

PMID:
19898877
7.

Ten-year experience with sevelamer and calcium salts as phosphate binders.

Raggi P, Vukicevic S, Moysés RM, Wesseling K, Spiegel DM.

Clin J Am Soc Nephrol. 2010 Jan;5 Suppl 1:S31-40. doi: 10.2215/CJN.05880809. Review.

8.

Emerging drugs for hyperphosphatemia.

Bellinghieri G, Santoro D, Savica V.

Expert Opin Emerg Drugs. 2007 Sep;12(3):355-65. Review.

PMID:
17874966
9.

Chronic kidney disease: Phosphate binder therapy--cracks in the tower of strength?

Evenepoel P, Meijers B.

Nat Rev Nephrol. 2012 Nov;8(11):615-6. doi: 10.1038/nrneph.2012.219. Epub 2012 Oct 9. No abstract available.

PMID:
23045230
10.

Oral phosphate binders for the management of serum phosphate levels in dialysis patients.

Mohammed I, Hutchison AJ.

J Ren Care. 2009 Mar;35 Suppl 1:65-70. doi: 10.1111/j.1755-6686.2009.00052.x. Review.

PMID:
19222734
11.

Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.

Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, Ortiz A, Kelly A, Chasan-Taber S, Duggal A, Fan S.

Nephrol Dial Transplant. 2009 Jan;24(1):278-85. doi: 10.1093/ndt/gfn488. Epub 2008 Sep 27.

PMID:
18820280
12.

Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis.

Kasai S, Sato K, Murata Y, Kinoshita Y.

Ther Apher Dial. 2012 Aug;16(4):341-9. doi: 10.1111/j.1744-9987.2012.01071.x. Epub 2012 May 11.

PMID:
22817122
13.

Phosphate binders in CKD: bad news or good news?

Drüeke TB, Massy ZA.

J Am Soc Nephrol. 2012 Aug;23(8):1277-80. doi: 10.1681/ASN.2012060569. Epub 2012 Jul 12. No abstract available.

14.

Optimising the treatment of hyperphosphatemia and vascular calcification in chronic kidney disease.

Cozzolino M, Brancaccio D.

Expert Opin Emerg Drugs. 2007 Sep;12(3):341-3.

PMID:
17874964
15.

Effectiveness and cost-efficacy of phosphate binders in hemodialysis.

Brunner-Ziegler S, Fröschl B, Hiebinger C, Zsifkovits J.

Ann Nutr Metab. 2011 Oct;58(4):315-9. doi: 10.1159/000331988. Epub 2011 Oct 7.

PMID:
21986491
16.

Pharmacology, efficacy and safety of oral phosphate binders.

Hutchison AJ, Smith CP, Brenchley PE.

Nat Rev Nephrol. 2011 Sep 6;7(10):578-89. doi: 10.1038/nrneph.2011.112. Review.

PMID:
21894188
17.

Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.

Patel L, Bernard LM, Elder GJ.

Clin J Am Soc Nephrol. 2016 Feb 5;11(2):232-44. doi: 10.2215/CJN.06800615. Epub 2015 Dec 14. Review.

18.

Effects of calcium on cardiovascular events in patients with kidney disease and in a healthy population.

West SL, Swan VJ, Jamal SA.

Clin J Am Soc Nephrol. 2010 Jan;5 Suppl 1:S41-7. doi: 10.2215/CJN.05860809. Review.

19.

Phosphate binders.

[No authors listed]

Med Lett Drugs Ther. 2006 Feb 13;48(1228):15-6. No abstract available.

PMID:
16467735
20.

Supplemental Content

Support Center